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CYCLOSPORINE A (CSA) SIGNIFICANTLY REDUCES THE CYTOTOXIC EF-
FECTS OF IN VITRO EXPANDED NK CELLS: IMPLICATIONS FOR ADOP-
TIVE NK CELL THERAPY IN THE SETTING OF ALLOGENEIC
HEMATOPOIETIC STEM CELL (HCT) TRANSPLANTATION
Yokoyama, H.1, Berg, M.1, Lundqvist, A.1, McCoy, J.P.2,
Srivastava, S.1, Smith, A.1, Childs, R.1. 1NHLBI, NIH, Bethesda,
MD; 2NHLBI, NIH, Bethesda, MD.
Recently, clinical trials have evaluated the impact of infusing nat-
ural killer (NK) cells following HCT). The impact of CSA, com-
monly used to prevent GVHD after HCT, on adoptive NK cell
function is unkown Hong et al reported the phenotype and function
of fresh NK cells was altered by CSA, showing CSA treated NK
cells elicited enhanced cytotoxicity against tumor targets. However,
the impact of CSA on in vitro expanded NK cell function and phe-
notype has not been explored. We analyzed the impact of culturing
fresh and in vitro expanded NK cells in physiological doses of CSA
(40, 200, 1000 ng/ml for 18 hrs)Fresh NK cells were obtained from
peripheral blood mononuclear cells of healthy donors using immu-
nomagnetic beads to isolate CD561/CD3- cells. NK cell expansion
in vitro was maximized by using irradiated EBV transformed B cells
as feeder cells in media containing IL-2 [500U/ml] for 12–14 days.
Compared to controls, CSA treated fresh NK cells had a significant
reduction in IL2-induced proliferation (stimulation index 0.51 6
0.1) and decreased TRAIL expression (MFI 17.3 vs 10.9, p 5
0.023). Furthermore, an ELISA assay showed fresh NK cells treated
with CSA had a significant reduction in IL-2 induced IFN-g pro-
duction (median 231 vs 57 pg/ml, p 5 0.025). In vitro expanded
NK cells cultured in CSA also showed a reduction in IL-2-induced
TRAIL expression (MFI 26.2 vs 16.3). Cytotoxicity assays showed
that at the highest dose of CSA (1000 ng/ml), freshly isolated NK
cells maintained their ability to kill K562 targets. In contrast, ex-
panded NK cells cultured in CSA for 18 hours with or without
IL-2 compared to controls had a significant reduction in the killing
of K562 cells (E:T 5 10:1, median 66 vs 43% lysis, p 5 0.011) and
RCC cells (E:T5 20:1, 78.5 vs 38.5% lysis). These data show CSA
alters the phenotype and function of both fresh and expanded NK
cells. More importantly, these experiments show NK cell TRAIL
mediated killing of tumor targets is significantly reduced when ex-
panded NK are exposed to physiologic doses of CSA in vitro. These
findings suggest the anti-tumor effects of in vitro expanded NK cells
could be hindered when adoptively infused in HCT patients receiv-
ing CSA.391
RITUXIMAB INFUSION AFTER ALLOGENEIC HCT PREVENTS DONOR B
CELL RECONSTITUTION AND ALLOIMMUNITY ONE YEAR POST TRANS-
PLANT
Sahaf, B.1, Chen, G.1, Boiko, J.1, Heydari, K.2, Arai, S.1, Miklos, D.1.
1Blood and Marrow Transplant, Stanford, CA; 2Pediatric Stem Cell
Transplant, Stanford, CA.
B cells are implicated in chronic graft-vs-host disease (cGVHD)
and anti-B cell rituximab is effective cGVHD therapy. We hypoth-
esize post allo-HCT rituximab therapy will prevent chronic
GVHD. Thirty-five MCL and CLL patients conditioned with non-
myeloablative total lymphoid irradiation and anti-thymocyte glob-
ulin (TLI-ATG) conditioning received rituximab 375 mg/m2 56,
63, 70, and 77 after allogeneic HCT.
Peripheral B cells are normal in number and of donor origin 3
months after TLI-ATG allo- HCT. With rituximab addition, pe-
ripheral CD191 B cells remained undetectable 9 months after
transplant; were first detected in 6/11 patients at 1 year and 8/8 pa-
tients at 1.5 years. These cells predominately expressed a memory
phenotype (CD191CD271, n 5 6). Hi-Dimension 12-color
FACS analysis of bone marrow aspirates collected day 56 (pre-ritux-
imab), 90, 180 and 365 days post-HCT showed lymphoid progen-
itors were prevalent days 56 and 90 (20–40%) and decline to 3–8%
of the lymphocytes, 365 days after HCT. Second, mature IgD1CD191 B cells are present day 56 pre-rituximab. Plasma cells are
unchanged throughout.
Plasma IgG levels decreased to 60% pre transplant levels at 6
months and 78% at one year. At 6, 9, and 12 months, EBV titer
was 76%, 104%, and 103% relative to pretransplant patient titers
demonstrating protective antibodies are maintained despite rituxi-
mab therapy presumably secreted from long-lived recipient CD20
negative plasma cells. Similar results are seen for tetanus. Our stron-
gest support for persistent recipient plasma cell immunity is allotype
discrimination of donor and recipient IgG2 showing the absence of
donor antibody development 1.5 years post-HCT. Further sup-
porting this, no allogeneic antibody responses have developed in
the five male with female donors against H-Y antigens.
In summary, rituximab therapy 2 months after allo-HCT pre-
vents donor B cell reconstitution one year after HCT, but protec-
tive recipient humoral immunity persists. Chronic GVHD
assessment requires further follow-up, but is promising.
Lymphoid Mature PlasmaDays after
HCTProgenitors
(CD341
CD1171)
(Pro B Cell
CD191CD341
CD10-)
(Pre B Cells
CD34-CD101
CD191)B Cells
(CD191
IgD1IgM1) CCells
(CD381
D1381)Total
IgG56, n 5 6
(Pre-ritux)22–25% 2–6% 0.1–4% 0.2–1% 0.7–1% 655 ug/dl
81% pre90, n 5 4 20–40% 2–9% 0.5–1.7% Not detected 0.5–3% 910 ug/dl
101% pre180, n 5 5 13–20% 5–12% 0.7% 1% 0.5–2% 507 ug/dl
60% pre365, n 5 5 3–8% 2–10% 0–0.5% 1–5% 0.5–3.7% 642 ug/dl
78%% range of cells gated on total lymphocytes; Not detected: within
the range of error for the measurement.392
DELAYED RECOVERY OF MYELOID (mDC) AND PLASMACYTOID (pDC)
DENDRITIC CELLS AT 3 MONTHS AFTER ALLOGENEIC HSC TRANSPLAN-
TATION CORRELATES WITH AN INCREASED TRANSPLANT-RELATED
AND OVERALL MORTALITY INDEPENDENTLY OF GVHD
Arpinati, M.1, Chirumbolo, G.1, Nicolini, B.1, De Vivo, A.1,
Bonifazi, F.1, Giannini, M.B.1, Giovannini, M.1, Bandini, G.1,
Martelli, V.1, Stanzani, M.1, Baccarani, M.1, Rondelli, D.2. 1University
of Bologna, Bologna, Italy; 2University of Illinois at Chicago, Chicago, IL.
Background: A low number of antigen presenting cells (APC) in
the peripheral blood 1 month after allogeneic HSC transplantation
has been previously associated with increased mortality. However,
the impact of APC recovery at later time points (3 through 12
months) after transplant has not been thoroughly investigated.
Aim: In this study we analyzed the factors affecting APC recovery
between 3 and 12 months after allogeneic HSC transplant and de-
termined its impact on the clinical outcome. Patients and
Methods: Blood samples from all patients undergoing an alloge-
neic HSC transplant in our institution from June 1999 through
June 2006 were analyzed. PB numbers of CD11c1 mDC,
CD1231 pDC and CD141 monocytes were determined based
on flow cytometry at 3 (n 5 161), 6 (n 5 127) and 12 months (n
5 80) after transplant. Results: Median numbers of PB APC at 3
months after transplant were (x106/L): mDC (7.4), pDC (2.5) and
monocytes (254), and then increased gradually at 6 (mDC 9.2,
pDC 3.4, monocytes 272) and 12 months (mDC 11.3, pDC 4.6,
monocytes 335). mDC recovery was delayed both at 3 and 6 months
in patients with advanced disease at transplant (p\ 0.00001 and
0.003, respectively), and acute GVHD grade II-IV (p 5 0.00009
and 0.01). Similarly, pDC recovery was delayed at 3 and 6 months
in patients with advanced disease (p 5 0.0001 and p 5 0.003) and
acute GVHD (p 5 0.0004 and p 5 0.02). Moreover, both mDC
and pDC levels at 6 months were reduced in patients with extensive
chronic GVHD (p 5 0.001 and p 5 0.0007 respectively). All other
analysed factors did not correlate with mDC and pDC recovery.
Also, mDC and pDC numbers at 12 months, as well as monocyte
